Tylenol maker Kenvue ousts CEO amid board's strategic review
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 14 2025
0mins
Should l Buy KVUE?
Source: Reuters
Executive Changes at Kenvue: Kenvue has fired CEO Thibaut Mongon amid investor pressure for improved performance, appointing Kirk Perry as interim CEO while also considering portfolio simplification and potential divestitures.
Financial Outlook and Strategic Review: The company is reviewing its operations with the help of advisors to evaluate possible sales of underperforming brands, particularly in its skin-health and beauty unit, and anticipates second-quarter profits aligning with analyst estimates.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KVUE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KVUE
Wall Street analysts forecast KVUE stock price to rise
8 Analyst Rating
1 Buy
7 Hold
0 Sell
Hold
Current: 17.380
Low
17.00
Averages
18.86
High
23.00
Current: 17.380
Low
17.00
Averages
18.86
High
23.00
About KVUE
Kenvue Inc. is a consumer health company. The Company’s differentiated portfolio of brands includes Tylenol, Neutrogena, Listerine, Johnson’s, BAND-AID, Aveeno, Zyrtec, and Nicorette. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. Its Self Care product categories include pain care; cough, cold, and allergy; digestive health; smoking cessation; eye care; and other products. Self Care segments include brands such as Tylenol, Motrin, Nicorette, Benadryl, Zyrtec, Zarbee’s, ORSLTM, Rhinocort, and Calpol. The Skin Health and Beauty segment is focused on face and body care, as well as hair, sun, and other products. The Essential Health segment includes oral care, baby care, women’s health, wound care, and other products. Its portfolio includes Self Care, Skin Health and Beauty, and Essential Health products which connect with consumers across North America, Asia Pacific (APAC), Europe, Middle East, and Africa (EMEA), and Latin America (LATAM).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Kimberly-Clark's Dividend Yield Soars to 5.3%
- Dividend Growth History: Kimberly-Clark has raised its dividend for 54 consecutive years, making it one of 60 companies that have paid and increased dividends for at least 50 years, showcasing its strong cash flow stability and long-term investor confidence.
- Yield Surge: The company's dividend yield has soared to 5.3% due to falling stock prices, and despite facing pressure on sales growth and profit margins, its operating cash flow remains sufficient to support dividends and share repurchase plans.
- Market Environment Challenges: Kimberly-Clark's stock is hovering around a 12-year low, impacted by inflation, weak consumer spending, and uncertainty surrounding the Kenvue acquisition, which has dampened investor sentiment in the short term.
- Long-Term Investment Opportunity: Despite short-term challenges, Kimberly-Clark's strong brands like Huggies and Kleenex maintain significant market positions, providing long-term investors with an opportunity to acquire shares at discounted prices.
See More
Kimberly-Clark Maintains Dividend Amid Earnings Decline
- Dividend Support Capability: Despite falling earnings, Kimberly-Clark can still support its dividend payments through operational cash flow, demonstrating financial resilience, especially as many high-yield stocks rely on debt.
- Acquisition Progress: Kimberly-Clark is expected to close its acquisition of Kenvue in the second half of 2026, a strategic move that will enhance its product portfolio and strengthen market competitiveness.
- Attracting Value Investors: With a dividend yield soaring to 5.3%, Kimberly-Clark stands out as an appealing option for income-focused investors, particularly as the S&P 500's dividend yield has dropped to 1.2%.
- Long-Term Growth Potential: Despite pressures from rising costs and weak consumer spending, Kimberly-Clark anticipates accelerating organic growth by the second half of 2026, with management aiming for at least 40% gross margins by the end of the decade, showcasing strong long-term growth potential.
See More
Strong Performance Fuels Promising Growth Outlook
- Significant Revenue Growth: Johnson & Johnson reported a 9.9% year-over-year revenue increase in Q1, reaching $24.06 billion, surpassing the market expectation of $23.63 billion, which underscores the company's robust performance in pharmaceuticals and medical technology, further solidifying its market position.
- Adjusted EPS Exceeds Expectations: The adjusted earnings per share for the first quarter stood at $2.70, exceeding the anticipated $2.66, reflecting effective management in cost control and profitability, which enhances investor confidence.
- Strong New Drug Sales: Sales of the blood cancer therapy Darzalex rose 22.5% year-over-year to $3.96 billion, exceeding market expectations, while Tremfya sales surged 68% to $1.61 billion, showcasing Johnson & Johnson's competitiveness and market demand in innovative pharmaceuticals.
- Optimistic Future Growth Guidance: Johnson & Johnson raised its full-year guidance, projecting revenue growth between 5.9% and 6.9%, with adjusted EPS expectations increased to a range of $11.45 to $11.65, indicating the company's confidence in future performance and positive market outlook.
See More
Johnson & Johnson vs. Pfizer: The Future of Healthcare Stocks
- Successful Spin-off: Johnson & Johnson's spin-off of its slow-growing consumer health division into Kenvue in 2023 has led to enhanced operational efficiency, with revenue reaching $88.8 billion in 2024 and projected to grow to between $99.5 billion and $100.5 billion by 2026, indicating strong growth potential in the healthcare market.
- Pfizer's Revenue Challenges: Pfizer's total revenue plummeted from approximately $100 billion in 2022 to $59.5 billion in 2023; despite efforts to strengthen its oncology pipeline through acquisitions like Seagen and Metsera, revenue is expected to remain flat in 2026, ranging from $59.5 billion to $62.5 billion, highlighting growth risks.
- Dividend Yield Comparison: Pfizer offers a dividend yield exceeding 6%, while Johnson & Johnson's yield stands at 2.1%; although Pfizer appears undervalued with a lower forward P/E ratio, its lower future earnings expectations may signal risks, whereas Johnson & Johnson's 60+ years of consistent dividend growth suggests greater sustainability.
- Market Outlook Analysis: Amid concerns over inflation, AI bubbles, and geopolitical risks, Johnson & Johnson's broad product portfolio, steady cash flow, and reliable dividend payments position it as a focal point for investors seeking potential shareholder returns over the next decade.
See More
Market Performance Analysis of Johnson & Johnson and Pfizer
- Johnson & Johnson Revenue Growth: Johnson & Johnson recorded $88.8 billion in revenue for 2024, with projections of $94.2 billion for 2025 and an expected range of $99.5 billion to $100.5 billion for 2026, indicating a clearer business focus and enhanced growth following the spin-off of its consumer health division.
- Pfizer Revenue Decline: Pfizer's total revenue plummeted from approximately $100 billion in 2022 to $59.5 billion in 2023; while its drug development efforts, particularly in oncology and the acquisition of Seagen, suggest future growth potential, the short-term revenue stability remains a concern.
- Dividend Yield Comparison: Pfizer offers a dividend yield exceeding 6%, compared to Johnson & Johnson's 2.1%; although Pfizer's yield appears more attractive, Johnson & Johnson's consistent dividend increases over the past 60 years reflect its financial stability and sustainability.
- Market Outlook Assessment: In the current economic climate, Johnson & Johnson demonstrates higher growth potential due to its diverse product portfolio and steady cash flow, leading analysts to favor its future earnings capability, making it a suitable focus for long-term investors.
See More
Investment Opportunities in Consumer Staples Stocks
- Dividend Durability: Despite short-term earnings pressure, General Mills (GIS) maintains a 127-year uninterrupted dividend payment history, currently yielding 6.7%, making it highly attractive for long-term income investors within the S&P 500.
- Brand Resilience: Hormel Foods (HRL) has raised its dividend for 59 consecutive years, and despite a 50% drop in share price since April 2022, its brands like Spam and Skippy remain market leaders, showcasing strong brand resilience and adaptability.
- Market Potential: Kenvue (KVUE), spun off from Johnson & Johnson in 2023, has seen its stock price drop about 30%, yet its product portfolio including Tylenol and Listerine shows a 3.2% revenue growth quarter-over-quarter, indicating defensibility and growth potential in consumer health.
- E-commerce Penetration: Church & Dwight (CHD) has achieved a 23% e-commerce channel share in global sales, with brands like Arm & Hammer contributing 70% of revenue, and is guiding for 3% to 4% organic sales growth in 2026, highlighting strong market prospects and investment value.
See More
Kimberly-Clark's Dividend Yield Soars to 5.3%
- Dividend Growth History: Kimberly-Clark has raised its dividend for 54 consecutive years, making it one of 60 companies that have paid and increased dividends for at least 50 years, showcasing its strong cash flow stability and long-term investor confidence.
- Yield Surge: The company's dividend yield has soared to 5.3% due to falling stock prices, and despite facing pressure on sales growth and profit margins, its operating cash flow remains sufficient to support dividends and share repurchase plans.
- Market Environment Challenges: Kimberly-Clark's stock is hovering around a 12-year low, impacted by inflation, weak consumer spending, and uncertainty surrounding the Kenvue acquisition, which has dampened investor sentiment in the short term.
- Long-Term Investment Opportunity: Despite short-term challenges, Kimberly-Clark's strong brands like Huggies and Kleenex maintain significant market positions, providing long-term investors with an opportunity to acquire shares at discounted prices.
See More
Kimberly-Clark Maintains Dividend Amid Earnings Decline
- Dividend Support Capability: Despite falling earnings, Kimberly-Clark can still support its dividend payments through operational cash flow, demonstrating financial resilience, especially as many high-yield stocks rely on debt.
- Acquisition Progress: Kimberly-Clark is expected to close its acquisition of Kenvue in the second half of 2026, a strategic move that will enhance its product portfolio and strengthen market competitiveness.
- Attracting Value Investors: With a dividend yield soaring to 5.3%, Kimberly-Clark stands out as an appealing option for income-focused investors, particularly as the S&P 500's dividend yield has dropped to 1.2%.
- Long-Term Growth Potential: Despite pressures from rising costs and weak consumer spending, Kimberly-Clark anticipates accelerating organic growth by the second half of 2026, with management aiming for at least 40% gross margins by the end of the decade, showcasing strong long-term growth potential.
See More
Strong Performance Fuels Promising Growth Outlook
- Significant Revenue Growth: Johnson & Johnson reported a 9.9% year-over-year revenue increase in Q1, reaching $24.06 billion, surpassing the market expectation of $23.63 billion, which underscores the company's robust performance in pharmaceuticals and medical technology, further solidifying its market position.
- Adjusted EPS Exceeds Expectations: The adjusted earnings per share for the first quarter stood at $2.70, exceeding the anticipated $2.66, reflecting effective management in cost control and profitability, which enhances investor confidence.
- Strong New Drug Sales: Sales of the blood cancer therapy Darzalex rose 22.5% year-over-year to $3.96 billion, exceeding market expectations, while Tremfya sales surged 68% to $1.61 billion, showcasing Johnson & Johnson's competitiveness and market demand in innovative pharmaceuticals.
- Optimistic Future Growth Guidance: Johnson & Johnson raised its full-year guidance, projecting revenue growth between 5.9% and 6.9%, with adjusted EPS expectations increased to a range of $11.45 to $11.65, indicating the company's confidence in future performance and positive market outlook.
See More
Johnson & Johnson vs. Pfizer: The Future of Healthcare Stocks
- Successful Spin-off: Johnson & Johnson's spin-off of its slow-growing consumer health division into Kenvue in 2023 has led to enhanced operational efficiency, with revenue reaching $88.8 billion in 2024 and projected to grow to between $99.5 billion and $100.5 billion by 2026, indicating strong growth potential in the healthcare market.
- Pfizer's Revenue Challenges: Pfizer's total revenue plummeted from approximately $100 billion in 2022 to $59.5 billion in 2023; despite efforts to strengthen its oncology pipeline through acquisitions like Seagen and Metsera, revenue is expected to remain flat in 2026, ranging from $59.5 billion to $62.5 billion, highlighting growth risks.
- Dividend Yield Comparison: Pfizer offers a dividend yield exceeding 6%, while Johnson & Johnson's yield stands at 2.1%; although Pfizer appears undervalued with a lower forward P/E ratio, its lower future earnings expectations may signal risks, whereas Johnson & Johnson's 60+ years of consistent dividend growth suggests greater sustainability.
- Market Outlook Analysis: Amid concerns over inflation, AI bubbles, and geopolitical risks, Johnson & Johnson's broad product portfolio, steady cash flow, and reliable dividend payments position it as a focal point for investors seeking potential shareholder returns over the next decade.
See More
Market Performance Analysis of Johnson & Johnson and Pfizer
- Johnson & Johnson Revenue Growth: Johnson & Johnson recorded $88.8 billion in revenue for 2024, with projections of $94.2 billion for 2025 and an expected range of $99.5 billion to $100.5 billion for 2026, indicating a clearer business focus and enhanced growth following the spin-off of its consumer health division.
- Pfizer Revenue Decline: Pfizer's total revenue plummeted from approximately $100 billion in 2022 to $59.5 billion in 2023; while its drug development efforts, particularly in oncology and the acquisition of Seagen, suggest future growth potential, the short-term revenue stability remains a concern.
- Dividend Yield Comparison: Pfizer offers a dividend yield exceeding 6%, compared to Johnson & Johnson's 2.1%; although Pfizer's yield appears more attractive, Johnson & Johnson's consistent dividend increases over the past 60 years reflect its financial stability and sustainability.
- Market Outlook Assessment: In the current economic climate, Johnson & Johnson demonstrates higher growth potential due to its diverse product portfolio and steady cash flow, leading analysts to favor its future earnings capability, making it a suitable focus for long-term investors.
See More
Investment Opportunities in Consumer Staples Stocks
- Dividend Durability: Despite short-term earnings pressure, General Mills (GIS) maintains a 127-year uninterrupted dividend payment history, currently yielding 6.7%, making it highly attractive for long-term income investors within the S&P 500.
- Brand Resilience: Hormel Foods (HRL) has raised its dividend for 59 consecutive years, and despite a 50% drop in share price since April 2022, its brands like Spam and Skippy remain market leaders, showcasing strong brand resilience and adaptability.
- Market Potential: Kenvue (KVUE), spun off from Johnson & Johnson in 2023, has seen its stock price drop about 30%, yet its product portfolio including Tylenol and Listerine shows a 3.2% revenue growth quarter-over-quarter, indicating defensibility and growth potential in consumer health.
- E-commerce Penetration: Church & Dwight (CHD) has achieved a 23% e-commerce channel share in global sales, with brands like Arm & Hammer contributing 70% of revenue, and is guiding for 3% to 4% organic sales growth in 2026, highlighting strong market prospects and investment value.
See More
